27.15
-0.37(-1.34%)
Currency In USD
| Previous Close | 27.52 |
| Open | 27.33 |
| Day High | 27.45 |
| Day Low | 26.7 |
| 52-Week High | 27.94 |
| 52-Week Low | 8.73 |
| Volume | 4.68M |
| Average Volume | 7.19M |
| Market Cap | 19.43B |
| PE | -23.21 |
| EPS | -1.17 |
| Moving Average 50 Days | 22.62 |
| Moving Average 200 Days | 16.1 |
| Change | -0.37 |
If you invested $1000 in Roivant Sciences Ltd. (ROIV) since IPO date, it would be worth $2,610.58 as of February 21, 2026 at a share price of $27.15. Whereas If you bought $1000 worth of Roivant Sciences Ltd. (ROIV) shares 5 years ago, it would be worth $2,585.71 as of February 21, 2026 at a share price of $27.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
GlobeNewswire Inc.
Feb 06, 2026 12:00 PM GMT
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001)All brepocitinib 45 mg patients achieved a clin
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
GlobeNewswire Inc.
Jan 23, 2026 9:15 PM GMT
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results f
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
GlobeNewswire Inc.
Dec 11, 2025 12:30 PM GMT
Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution, Roivant announces positive updates to timing guid